CU20200084A7 - Derivados sustituidos de la carboxamida dihidropirazolo pirazina - Google Patents

Derivados sustituidos de la carboxamida dihidropirazolo pirazina

Info

Publication number
CU20200084A7
CU20200084A7 CU2020000084A CU20200084A CU20200084A7 CU 20200084 A7 CU20200084 A7 CU 20200084A7 CU 2020000084 A CU2020000084 A CU 2020000084A CU 20200084 A CU20200084 A CU 20200084A CU 20200084 A7 CU20200084 A7 CU 20200084A7
Authority
CU
Cuba
Prior art keywords
dihydropirazolo
pirazine
carboxamide
substitute derivatives
substitute
Prior art date
Application number
CU2020000084A
Other languages
English (en)
Inventor
Thomas Brumby
Anja Buchmuller
Alexander Ehmann
Markus Follmann
Xiang Gao
Fabienne Gaugaz
Christoph Gerdes
Michael Gerisch
Nunez Eloisa Jimenez
Elisabeth Kerten
Dieter Lang
Lutz Lehmann
Niels Lindner
Steffen Muller
Hernández Nuria Ortega
Elisabeth Pook
Martina Schafer
Karl-Heinz Schlemmer
Georg Schmidt
Rudolf Schohe-Loop
Frank Sussmeier
Andreas Timmermann
Vivian Wang
Yafeng Wang
Stefanie Zimmermann
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of CU20200084A7 publication Critical patent/CU20200084A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

<p>La invención se refiere a un compuesto de la fórmula (I)</p> <p>ESPACIO PARA FÓRMULA</p> <p>útil para preparar medicamentos para el tratamiento y/o la profilaxis de enfermedades, en particular de trastornos cardiovasculares, preferentemente de trastornos trombóticos o tromboembólicos y diabetes y también de trastornos urogenitales y oftálmicos.</p> <p>Se refiere también al método de preparación de dicho compuesto.</p>
CU2020000084A 2018-05-17 2019-05-10 Derivados sustituidos de la carboxamida dihidropirazolo pirazina CU20200084A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018087249 2018-05-17
PCT/EP2019/062005 WO2019219517A1 (en) 2018-05-17 2019-05-10 Substituted dihydropyrazolo pyrazine carboxamide derivatives

Publications (1)

Publication Number Publication Date
CU20200084A7 true CU20200084A7 (es) 2021-06-08

Family

ID=66625151

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000084A CU20200084A7 (es) 2018-05-17 2019-05-10 Derivados sustituidos de la carboxamida dihidropirazolo pirazina

Country Status (25)

Country Link
US (1) US20220324865A1 (es)
EP (1) EP3793559A1 (es)
JP (1) JP2021523910A (es)
KR (1) KR20210013084A (es)
CN (1) CN112469412A (es)
AR (1) AR114906A1 (es)
AU (1) AU2019270142A1 (es)
BR (1) BR112020021612A2 (es)
CA (1) CA3100221A1 (es)
CL (1) CL2020002974A1 (es)
CO (1) CO2020014201A2 (es)
CR (1) CR20200554A (es)
CU (1) CU20200084A7 (es)
EA (1) EA202092779A1 (es)
EC (1) ECSP20072258A (es)
JO (1) JOP20200294A1 (es)
MA (1) MA52623A (es)
MX (1) MX2020012201A (es)
NI (1) NI202000083A (es)
PE (1) PE20210856A1 (es)
PH (1) PH12020551973A1 (es)
SG (1) SG11202010679SA (es)
TW (1) TW202012408A (es)
UY (1) UY38237A (es)
WO (1) WO2019219517A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
CN115819417A (zh) 2016-09-09 2023-03-21 因赛特公司 作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
EP3755703B1 (en) 2018-02-20 2022-05-04 Incyte Corporation N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
BR112022002059A2 (pt) 2019-08-06 2022-06-07 Incyte Corp Formas sólidas de um inibidor de hpk1
WO2021094210A1 (en) * 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
WO2021094208A1 (en) * 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted imidazo pyrimidine ep3 antagonists
WO2021094209A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
CN114236017B (zh) * 2022-02-23 2022-06-07 深圳市海滨制药有限公司 一种棕榈酸抗坏血酸酯及其杂质的检测方法
WO2024220803A1 (en) * 2023-04-19 2024-10-24 Bristol-Myers Squibb Company Use of milvexian in the treatment and prevention of thrombotic conditions in patients with atrial fibrilation

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
US7476666B2 (en) * 2004-06-09 2009-01-13 Merck & Co., Inc. HIV integrase inhibitors
DE102004054665A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte bi- und tricyclische Pyrazol-Derivate Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
DE102007032349A1 (de) * 2007-07-11 2009-01-15 Bayer Healthcare Ag Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
CA2695989A1 (en) 2007-08-10 2009-02-19 Glaxosmithkline Llc Certain nitrogen containing bicyclic chemical entities for treating viral infections
CA2708176A1 (en) 2007-12-21 2009-07-02 Genentech, Inc. Azaindolizines and methods of use
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
UA109650C2 (xx) 2010-02-27 2015-09-25 Біс-арилзв'язані арилтриазолони та їх застосування
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EA201390060A1 (ru) 2010-07-09 2013-07-30 Байер Интеллектуэль Проперти Гмбх Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
US8791162B2 (en) 2011-02-14 2014-07-29 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
CA2868620C (en) 2012-03-28 2020-02-25 Dieter Dorsch Bicyclic pyrazinone derivatives
KR20150130491A (ko) 2013-03-13 2015-11-23 제넨테크, 인크. 피라졸로 화합물 및 그것의 용도
CA2926568C (en) * 2013-10-09 2017-09-05 Pfizer Inc. Antagonists of prostaglandin ep3 receptor
EP3063150B1 (de) * 2013-10-30 2017-11-22 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
EP3112369A4 (en) 2014-02-27 2017-09-20 The University of Tokyo Fused pyrazole derivative having autotaxin inhibitory activity
SI3215498T1 (sl) 2014-11-03 2018-11-30 Bayer Pharma Aktiengesellschaft Hidroksialkil-substituirani derivati feniltriazola in njihove uporabe
EP3237401B1 (en) 2014-12-22 2019-03-06 Pfizer Inc Antagonists of prostaglandin ep3 receptor
CN109071546B (zh) 2016-02-24 2021-03-02 辉瑞大药厂 作为jak抑制剂的吡唑并[1,5-a]吡嗪-4-基衍生物

Also Published As

Publication number Publication date
EA202092779A1 (ru) 2021-02-02
JP2021523910A (ja) 2021-09-09
SG11202010679SA (en) 2020-11-27
BR112020021612A2 (pt) 2021-01-26
AU2019270142A1 (en) 2020-11-12
CO2020014201A2 (es) 2021-03-08
KR20210013084A (ko) 2021-02-03
MA52623A (fr) 2021-03-24
MX2020012201A (es) 2021-01-29
ECSP20072258A (es) 2020-12-31
CA3100221A1 (en) 2019-11-21
NI202000083A (es) 2021-03-11
US20220324865A1 (en) 2022-10-13
JOP20200294A1 (ar) 2020-11-17
EP3793559A1 (en) 2021-03-24
PE20210856A1 (es) 2021-05-18
CR20200554A (es) 2021-01-12
UY38237A (es) 2019-11-29
AR114906A1 (es) 2020-10-28
CN112469412A (zh) 2021-03-09
CL2020002974A1 (es) 2021-03-05
WO2019219517A1 (en) 2019-11-21
PH12020551973A1 (en) 2021-08-02
TW202012408A (zh) 2020-04-01

Similar Documents

Publication Publication Date Title
CU20200084A7 (es) Derivados sustituidos de la carboxamida dihidropirazolo pirazina
CL2018000039A1 (es) Derivados de oxopiridina sustituidos
PH12019502264A1 (en) Fused imidazo-piperidine jak inhibitors compound
MX2020007265A (es) Derivados de rapamicina.
EA201991693A1 (ru) Производное пиридина в качестве ингибитора ask1 и способ его получения и применения
EA201891917A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
TN2016000268A1 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2.
MX2022015106A (es) Proceso para preparar tapinarof.
PH12015502248B1 (en) 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors
PA8784001A1 (es) Oxazolidinonas sustituidas y su uso
MX386256B (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
CL2021001613A1 (es) Derivados de oxopiridina sustituidos
JOP20200100A1 (ar) مشتقات بيرازولو-بيرولو-بيريميدين-ديون جديدة كمثبِّطات لـ p2x3
MX2018014298A (es) Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3 -il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino) -benzamida.
MX2018008307A (es) Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk).
EA201792234A1 (ru) Новые соединения пиридиния
MX2019014272A (es) Compuestos policiclicos y usos de los mismos.
MX2020010985A (es) Procedimiento para la preparacion de iloprost.
WO2017029642A3 (en) Novel polymorphs of dolutegravir and salts thereof
WO2016044433A3 (en) Metformin derivatives
TH1701002063A (th) ตัวยับยั้งแอลโดสเทอโรนซินเธส
EA201891690A1 (ru) Агонист fxr, представляющий собой производное стероидов
MX2016014692A (es) Polimorfos cristalinos novedosos de derivados de piridina y metodo para producirlos.